サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798889

ガドクワトランの世界市場

Gadoquatrane

出版日
ページ情報
英文 273 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ガドクワトランの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 273 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ガドクワトランの世界市場は2030年までに24億米ドルに達する

2024年に19億米ドルと推定されるガドクワトランの世界市場は、2024年から2030年にかけてCAGR 3.4%で成長し、2030年には24億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるスクリーニング用途は、CAGR 2.7％を記録し、分析期間終了までに14億米ドルに達すると予測されます。診断アプリケーション分野の成長率は、分析期間でCAGR 4.6％と推定されます。

米国市場は5億2,780万米ドルと推定、中国はCAGR6.2％で成長予測

米国のガドクワトラン市場は、2024年に5億2,780万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,620万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.6%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界のガドクワトラン市場- 主要動向と促進要因のまとめ

ガドクワトランが画像診断で注目される理由とは？

ガドクワトランは、磁気共鳴画像法（MRI）で使用される次世代の大環状ガドリニウム系造影剤（GBCA）です。特に繰り返し撮影を必要とする患者に対して、安全性を高めながら撮影性能を向上させる目的で開発されました。ガドクワトランの分子構造は、ガドリニウムイオンを強く結合させるため、解離のリスクを最小限に抑え、ガドリニウムが組織に滞留する可能性を低減します。これは、旧世代の造影剤に関連した長期的なガドリニウム蓄積に対する懸念を受けて、重要な考慮事項となっています。

臨床の現場では、ガドクワトランは血管や臓器、腫瘍や病変などの病的構造をより鮮明に描出するために使用されます。その強力な弛緩特性は、低線量で高解像度のイメージングをサポートし、特に小児や腎機能障害のある患者において有用です。神経学、腫瘍学、心臓血管系の診断において、高精度で高コントラストなMRIの需要が高まり続ける中、ガドクワトランは、診断の明瞭性に優れ、より安全な代替手段としてますます注目されています。この製品は、画質と患者の安全性の両立を目指す放射線科で採用されています。

製剤の進歩と安全性プロファイルは、どのように採用を支えているのでしょうか？

ガドクワトランのような大環状造影剤は、化学的安定性と遊離ガドリニウムイオンの放出傾向が低いことで知られています。ガドクワトランは、この基盤の上に、運動学的不活性性の向上と、腎機能が低下した患者におけるガドリニウムに関連するまれではあるが重篤な症状である腎性全身性線維症（NSF）のリスクの低減を提供しています。これらの特徴は、規制当局への申請や臨床プロトコールで強調されており、ガドクワトランをより幅広い患者群に適したものにしています。

この薬剤の臨床的な磁場強度における高い緩和性は、スキャン時間の短縮と画像のコントラストの鮮明化を可能にします。これにより、より効率的な撮像ワークフローと、軟部組織の異常検出における診断精度の向上が可能となります。標準的なMRI装置や造影剤供給システムとの互換性により、既存の画像診断セットアップにシームレスに統合できるため、ヘルスケアプロバイダーはインフラを大幅にアップグレードすることなく容易に移行できます。

どのような臨床・規制動向が市場の可能性を形成しているか？

MRI検査件数は、神経疾患、がん検診、心血管疾患評価の増加により、世界的に増加し続けています。こうした動向により、ヘルスケアプロバイダーは、安全性の懸念を最小限に抑えながら優れた画質を提供する造影剤を求めるようになっています。規制当局も造影剤の安全性を重視する姿勢を強めており、ガドリニウム放出リスクの低い薬剤の使用を奨励しています。ガドクワトランはこのような嗜好に合致しており、病院や画像診断センターにとって好ましい選択肢となっています。

医療機関での採用は、臨床ガイドラインや購入フレームワークへの大環状薬剤の組み入れの増加によって支えられています。先進的な診断手技を優遇する償還政策も、特に新興国市場での普及を後押ししています。ガドリニウム滞留に対する認識が臨床医や患者の間で高まるにつれて、より安全な造影剤に対する需要は高まり続けると予想されます。現在進行中の臨床研究により、中枢神経系病変の検出や小児放射線学など、特殊な画像診断アプリケーションにおけるガドクワトランの使用範囲が拡大しています。

ガドクワトラン市場の成長はいくつかの要因によって牽引される...

ガドクワトラン市場の成長は、より安全なガドリニウムベースのMRI造影剤に対する需要の増加、画像診断量の拡大、薬剤製剤の技術改良など、いくつかの要因によって牽引されています。ガドリニウムの組織滞留に対する懸念の高まりは、より高い運動安定性を持つ大環状化合物へのシフトを促しています。ガドクワトランの低用量で高い弛緩性を提供する能力は、神経学、腫瘍学、血管診断における画像診断結果の改善をサポートします。低リスク造影剤に対する規制上のサポートと、進化する安全基準との整合性は、病院や外来での市場拡大を促進します。ヘルスケアプロバイダーが安全性が実証された効率的で高解像度のイメージングツールを求める中、ガドクワトランは先進MRI診断における次世代の選択肢として支持を集めています。

セグメント

アプリケーション（スクリーニングアプリケーション、診断アプリケーション）;エンドユーザー（病院エンドユーザー、診断センターエンドユーザー、専門クリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Bayer AG
  • Bracco Imaging S.p.A.
  • Canon Medical Systems
  • Curium Pharma
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Glenmark Pharmaceuticals
  • Guerbet Group
  • Hitachi Medical Systems
  • Lantheus Medical Imaging
  • Mallinckrodt Pharmaceuticals
  • Nihon Medi-Physics
  • Philips Healthcare
  • Siemens Healthineers
  • Sinerga S.p.A.
  • Shenzhen YHLO Biotech
  • Simcere Pharmaceutical Group
  • Shenzhen Wanliyang Medical
  • Troikaa Pharmaceuticals
  • Unistar Medical

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38862

Global Gadoquatrane Market to Reach US$2.4 Billion by 2030

The global market for Gadoquatrane estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Screening Application, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Diagnosis Application segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$527.8 Million While China is Forecast to Grow at 6.2% CAGR

The Gadoquatrane market in the U.S. is estimated at US$527.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$466.2 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gadoquatrane Market - Key Trends & Drivers Summarized

Why Is Gadoquatrane Gaining Attention in Diagnostic Imaging?

Gadoquatrane is a next-generation macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI). It has been developed to offer improved imaging performance with enhanced safety features, particularly for patients requiring repeated scans. Gadoquatrane’s molecular structure provides strong binding of gadolinium ions, minimizing the risk of dissociation and reducing the likelihood of gadolinium retention in tissues. This has become an important consideration following concerns over long-term gadolinium accumulation associated with earlier-generation contrast agents.

In clinical practice, gadoquatrane is used to enhance visualization of blood vessels, organs, and pathological structures such as tumors and lesions. Its strong relaxivity properties support high-resolution imaging at lower doses, which is especially valuable in pediatric and renal-impaired patients. As demand for accurate, high-contrast MRI continues to rise in neurology, oncology, and cardiovascular diagnostics, gadoquatrane is increasingly viewed as a safer alternative with superior diagnostic clarity. The product is being adopted by radiology departments aiming to balance image quality with patient safety.

How Are Formulation Advances and Safety Profiles Supporting Adoption?

Macrocyclic contrast agents like gadoquatrane are known for their chemical stability and low propensity to release free gadolinium ions. Gadoquatrane builds on this foundation by offering enhanced kinetic inertness and reduced risk of nephrogenic systemic fibrosis (NSF), a rare but serious condition linked to gadolinium in patients with impaired kidney function. These characteristics are being emphasized in regulatory filings and clinical protocols, making gadoquatrane suitable for broader patient groups.

Another factor aiding adoption is the agent’s high relaxivity at clinical field strengths, which allows for shorter scan times and sharper image contrasts. This enables more efficient imaging workflows and greater diagnostic precision in detecting soft tissue abnormalities. Compatibility with standard MRI equipment and contrast delivery systems allows seamless integration into existing imaging setups, making it easier for healthcare providers to transition without significant infrastructure upgrades.

What Clinical and Regulatory Trends Are Shaping Market Potential?

MRI scan volumes continue to increase globally, driven by rising incidence of neurological disorders, cancer screening, and cardiovascular disease evaluation. These trends are leading healthcare providers to seek contrast agents that offer superior image quality with minimal safety concerns. Regulatory bodies are increasingly focusing on contrast agent safety, encouraging the use of agents with lower gadolinium release risk. Gadoquatrane aligns well with such preferences, positioning it as a preferred option for hospitals and diagnostic imaging centers.

Institutional adoption is supported by growing inclusion of macrocyclic agents in clinical guidelines and purchasing frameworks. Reimbursement policies that favor advanced diagnostic procedures also support wider uptake, particularly in developed markets. As awareness around gadolinium retention grows among clinicians and patients, demand for safer contrast solutions is expected to continue rising. Ongoing clinical studies are expanding the scope of gadoquatrane in specialized imaging applications, such as CNS lesion detection and pediatric radiology.

Growth in the Gadoquatrane Market Is Driven by Several Factors…

Growth in the gadoquatrane market is driven by several factors including increasing demand for safer gadolinium-based MRI contrast agents, expanding diagnostic imaging volumes, and technological improvements in agent formulation. Rising concern over tissue retention of gadolinium is prompting a shift toward macrocyclic compounds with higher kinetic stability. Gadoquatrane’s ability to deliver high relaxivity at low doses supports improved imaging outcomes in neurology, oncology, and vascular diagnostics. Regulatory support for low-risk contrast agents and alignment with evolving safety standards facilitate market expansion across hospital and outpatient settings. As healthcare providers seek efficient, high-resolution imaging tools with proven safety profiles, gadoquatrane is gaining traction as a next-generation option in advanced MRI diagnostics.

SCOPE OF STUDY:

The report analyzes the Gadoquatrane market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Screening Application, Diagnosis Application); End-User (Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Bayer AG
  • Bracco Imaging S.p.A.
  • Canon Medical Systems
  • Curium Pharma
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Glenmark Pharmaceuticals
  • Guerbet Group
  • Hitachi Medical Systems
  • Lantheus Medical Imaging
  • Mallinckrodt Pharmaceuticals
  • Nihon Medi-Physics
  • Philips Healthcare
  • Siemens Healthineers
  • Sinerga S.p.A.
  • Shenzhen YHLO Biotech
  • Simcere Pharmaceutical Group
  • Shenzhen Wanliyang Medical
  • Troikaa Pharmaceuticals
  • Unistar Medical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Gadoquatrane - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Safer and More Stable MRI Contrast Agents Drives Clinical Interest in Gadoquatrane Formulations
    • Increased Concerns Over Gadolinium Retention in Patients With Renal Impairment Spur Development of Macrocyclic Agents Like Gadoquatrane
    • Growth in MRI Procedures Across Oncology, Neurology, and Cardiovascular Imaging Supports Adoption of Novel Contrast Agents
    • Advancements in Contrast Agent Design Enhance Stability, Relaxivity, and Diagnostic Accuracy in Gadoquatrane-Based Products
    • Surge in Gadolinium-Free and Low-Dose Alternatives Positions Gadoquatrane as a Viable Macrocyclic Solution With Enhanced Safety Margins
    • Expansion of Pediatric and Geriatric Imaging Services Highlights Demand for Well-Tolerated, Low-Toxicity Contrast Media
    • Improved Shelf-Life, Storage Stability, and Compatibility With MRI Modalities Support Hospital Adoption of Gadoquatrane
    • Increasing Investment in Radiopharmaceutical R&D Creates Opportunities for Dual-Function Imaging and Contrast Agents
    • Use in High-Resolution Brain and Vascular Imaging Scenarios Expands Clinical Applications for Gadoquatrane-Based Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gadoquatrane Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION